Corrigendum to “α-Asarone attenuates microglia-mediated neuroinflammation by inhibiting NF kappa B activation and mitigates MPTP-induced behavioral deficits in a mouse model of Parkinson's disease” [Neuropharm 97 (2015) 46–57] (S0028390815001689) (10.1016/j.neuropharm.2015.04.037);α-Asarone attenuates microglia-mediated neuroinflammation by inhibiting NF kappa B activation and mitigates MPTP-induced behavioral deficits in a mouse model of Parkinson's disease

Neuropharmacology

Volumn 97, Issue , 2015, Pages 46-57

  Kim, Byung Wook ^a   Koppula, Sushruta ^a   Kumar, Hemant ^a   Park, Ju Young ^b   Kim, Il Woung ^a   More, Sandeep V ^a   Kim, In Su ^a   Han, Sang Don ^c   Kim, Si Kwan ^a   Yoon, Sung Hwa ^b   Choi, Dong Kug ^a  

^a Konkuk University   (South Korea)

^b Ajou University   (South Korea)

^c Konkuk University School of Medicine   (South Korea)

Author keywords

Microglia; MPTP; Neuroinflammation; Parkinson's disease; Asarone

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA ASARONE; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; ANISOLE DERIVATIVE; ASARONE; NEUROPROTECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR DISORDER; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE ACTIVATION; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROGLIA; MOUSE; MPTP-INDUCED PARKINSONISM; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; POLE TEST; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; Y-MAZE TEST; ANIMAL; BRAIN; C57BL MOUSE; CELL LINE; CHEMISTRY; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; DRUG EFFECTS; IMMUNOLOGY; IMMUNOMODULATION; ISOLATION AND PURIFICATION; MAZE TEST; METABOLISM; MOTOR ACTIVITY; MPTP POISONING; PATHOLOGY; PHYSIOLOGY;

ANIMALS; ANISOLES; BRAIN; CELL LINE; CYTOKINES; DOPAMINERGIC NEURONS; DOSE-RESPONSE RELATIONSHIP, DRUG; LIPOPOLYSACCHARIDES; MALE; MAZE LEARNING; MICE, INBRED C57BL; MICROGLIA; MOTOR ACTIVITY; MPTP POISONING; NEUROIMMUNOMODULATION; NEUROPROTECTIVE AGENTS; NF-KAPPA B;

EID: 84930677075     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2017.02.023     Document Type: Erratum

References (88)

1. W.K. Alderton, C.E. Cooper, and R.G. Knowles Nitric oxide synthases: structure, function and inhibition Biochem. J. 357 2001 593 615
2. E. Aoki, R. Yano, H. Yokoyama, H. Kato, and T. Araki Role of nuclear transcription factor kappa B (NF-kappaB) for MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine)-induced apoptosis in nigral neurons of mice Exp. Mol. Pathol. 86 2009 57 64
3. I. Atreya, R. Atreya, and M.F. Neurath NF-kappaB in inflammatory bowel disease J. Intern Med. 263 2008 591 596
4. K.J. Barnham, C.L. Masters, and A.I. Bush Neurodegenerative diseases and oxidative stress Nat. Rev. Drug Discov. 3 2004 205 214
5. M.K. Barthwal, N. Srivastava, and M. Dikshit Role of nitric oxide in a progressive neurodegeneration model of Parkinson's disease in the rat Redox Rep. 6 2001 297 302
6. M.L. Block, X. Wu, Z. Pei, G. Li, T. Wang, L. Qin, B. Wilson, J. Yang, J.S. Hong, and B. Veronesi Nanometer size diesel exhaust particles are selectively toxic to dopaminergic neurons: the role of microglia, phagocytosis, and NADPH oxidase FASEB J. 18 2004 1618 1620
7. M.L. Block, L. Zecca, and J.S. Hong Microglia-mediated neurotoxicity: uncovering the molecular mechanisms Nat. Rev. Neurosci. 8 2007 57 69
8. D. Blum-Degen, T. Muller, W. Kuhn, M. Gerlach, H. Przuntek, and P. Riederer Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients Neurosci. Lett. 202 1995 17 20
9. Y. Cao, T. Luetkens, S. Kobold, Y. Hildebrandt, M. Gordic, N. Lajmi, S. Meyer, K. Bartels, A.R. Zander, C. Bokemeyer, N. Kroger, and D. Atanackovic The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients Exp. Hematol. 38 2010 860 867
10. S.H. Choi, E.H. Joe, S.U. Kim, and B.K. Jin Thrombin-induced microglial activation produces degeneration of nigral dopaminergic neurons invivo J.Neurosci. 23 2003 5877 5886
11. Y. Choi, M.K. Lee, S.Y. Lim, S.H. Sung, and Y.C. Kim Inhibition of inducible NO synthase, cyclooxygenase-2 and interleukin-1beta by torilin is mediated by mitogen-activated protein kinases in microglial BV2 cells Br. J. Pharmacol. 156 2009 933 940
12. F. Cicchetti, A.L. Brownell, K. Williams, Y.I. Chen, E. Livni, and O. Isacson Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging Eur. J. Neurosci. 15 2002 991 998
13. A. Czlonkowska, M. Kohutnicka, I. Kurkowska-Jastrzebska, and A. Czlonkowski Microglial reaction in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced Parkinson's disease mice model Neurodegeneration 5 1996 137 143
14. N.R. Das, R.P. Gangwal, M.V. Damre, A.T. Sangamwar, and S.S. Sharma APPAR-beta/delta agonist is neuroprotective and decreases cognitive impairment in a rodent model of Parkinson's disease Curr. Neurovasc Res. 11 2014 114 124
15. A.L. De Lella Ezcurra, M. Chertoff, C. Ferrari, M. Graciarena, and F. Pitossi Chronic expression of low levels of tumor necrosis factor-alpha in the substantia nigra elicits progressive neurodegeneration, delayed motor symptoms and microglia/macrophage activation Neurobiol. Dis. 37 2010 630 640
16. T. Dehmer, J. Lindenau, S. Haid, J. Dichgans, and J.B. Schulz Deficiency of inducible nitric oxide synthase protects against MPTP toxicity invivo J.Neurochem. 74 2000 2213 2216
17. K. Fifel, O. Dkhissi-Benyahya, and H.M. Cooper Lack of long-term changes in circadian, locomotor, and cognitive functions in acute and chronic MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse models of Parkinson's disease Chronobiol Int. 30 2013 741 755
18. S.H. Fox, N. Visanji, G. Reyes, P. Huot, J. Gomez-Ramirez, T. Johnston, and J.M. Brotchie Neuropsychiatric behaviors in the MPTP marmoset model of Parkinson's disease Can. J. Neurol. Sci. 37 2010 86 95
19. H.M. Gao, J. Jiang, B. Wilson, W. Zhang, J.S. Hong, and B. Liu Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease J.Neurochem. 81 2002 1285 1297
20. H.M. Gao, B. Liu, and J.S. Hong Critical role for microglial NADPH oxidase in rotenone-induced degeneration of dopaminergic neurons J.Neurosci. 23 2003 6181 6187
21. L. Garduno, M. Salazar, S. Salazar, M. Morelos, F. Labarrios, J. Tamariz, and G. Chamorro Hypolipidaemic activity of alpha-asarone in mice J.Ethnopharmacol. 55 1997 161
22. M. Gerlach, and P. Riederer Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man J.Neural Transm. 103 1996 987 1041
23. O. Ghribi, M.M. Herman, P. Pramoonjago, and J. Savory MPP+ induces the endoplasmic reticulum stress response in rabbit brain involving activation of the ATF-6 and NF-kappaB signaling pathways J.Neuropathol. Exp. Neurol. 62 2003 1144 1153
24. F. González-Scarano, and G. Baltuch Microglia as mediators of inflammatory and degenerative diseases Annu Rev. Neurosci. 1999 219 240
25. E.C. Hirsch, and S. Hunot Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol. 8 2009 382 397
26. E.C. Hirsch, S. Vyas, and S. Hunot Neuroinflammation in Parkinson's disease Park. Relat. Disord. 1 18 Suppl. l 2012 S210 S212
27. U. Hofmann, S. Heuer, K. Meder, J. Boehler, V. Lange, T. Quaschning, G. Ertl, and A. Bonz The proinflammatory cytokines TNF-alpha and IL-1 beta impair economy of contraction in human myocardium Cytokine 39 2007 157 162
28. S. Hunot, B. Brugg, D. Ricard, P.P. Michel, M.P. Muriel, M. Ruberg, B.A. Faucheux, Y. Agid, and E.C. Hirsch Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease Proc. Natl. Acad. Sci. USA 94 1997 7531 7536
29. V. Jackson-Lewis, and R.J. Smeyne MPTP and SNpc DA neuronal vulnerability: role of dopamine, superoxide and nitric oxide in neurotoxicity Minireview. Neurotox. Res. 7 2005 193 202
30. N.R. Jeon, S. Koppula, B.W. Kim, S.H. Park, H.W. Lee, and D.K. Choi MMHD [(S,E)-2-methyl-1-(2-methylthiazol-4-yl) hexa-1,5-dien-ol], a novel synthetic compound derived from epothilone, suppresses nuclear factor-kappaB-mediated cytokine expression in lipopolysaccharide-stimulated BV-2 microglia J. Pharmacol. Sci. 112 2010 158 166
31. J. Jiang, J.J. Kim, D.Y. Kim, M.K. Kim, N.H. Oh, S. Koppula, P.J. Park, D.K. Choi, Y.K. Shin, I.H. Kim, T.B. Kang, and K.H. Lee Acorus gramineus inhibits microglia mediated neuroinflammation and prevents neurotoxicity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mouse model of Parkinson's disease J. Ethnopharmacol. 144 2012 506 513
32. M. Jin, B.W. Kim, S. Koppula, I.S. Kim, J.H. Park, H. Kumar, and D.K. Choi Molecular effects of activated BV-2 microglia by mitochondrial toxin 1-methyl-4-phenylpyridinium Neurotoxicology 33 2012 147 155
33. S. Karunakaran, and V. Ravindranath Activation of p38 MAPK in the substantia nigra leads to nuclear translocation of NF-kappaB in MPTP-treated mice: implication in Parkinson's disease J. Neurochem. 109 2009 1791 1799
34. B.W. Kim, S. Koppula, S.S. Hong, S.B. Jeon, J.H. Kwon, B.Y. Hwang, E.J. Park, and D.K. Choi Regulation of microglia activity by glaucocalyxin-A: attenuation of lipopolysaccharide-stimulated neuroinflammation through NF-kappaB and p38 MAPK signaling pathways PLoS One 8 2013 e55792
35. B.W. Kim, S. Koppula, I.S. Kim, H.W. Lim, S.M. Hong, S.D. Han, B.Y. Hwang, and D.K. Choi Anti-neuroinflammatory activity of Kamebakaurin from Isodon japonicus via inhibition of c-Jun NH-terminal kinase and p38 mitogen-activated protein kinase pathway in activated microglial cells J. Pharmacol. Sci. 116 2011 296 308
36. D.H. Kim, S.J. Jeon, K.H. Son, J.W. Jung, S. Lee, B.H. Yoon, J.J. Lee, Y.W. Cho, J.H. Cheong, K.H. Ko, and J.H. Ryu The ameliorating effect of oroxylin A on scopolamine-induced memory impairment in mice Neurobiol. Learn Mem. 87 2007 536 546
37. J.H. Kim, H.W. Lee, J. Hwang, J. Kim, M.J. Lee, H.S. Han, W.H. Lee, and K. Suk Microglia-inhibiting activity of Parkinson's disease drug amantadine Neurobiol. Aging 33 2012 2145 2159
38. S.U. Kim, and J. de Vellis Microglia in health and disease J. Neurosci. Res. 81 2005 302 313
39. W.G. Kim, R.P. Mohney, B. Wilson, G.H. Jeohn, B. Liu, and J.S. Hong Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia J. Neurosci. 20 2000 6309 6316
40. C. Knott, G. Stern, and G.P. Wilkin Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2 Mol. Cell. Neurosci. 16 2000 724 739
41. L. Kokkinidis, M.D. Walsh, R. Lahue, and H. Anisman Tolerance to d-amphetamine: behavioral specificity Life Sci. 18 1976 913 917
42. S. Koppula, H. Kumar, I.S. Kim, and D.K. Choi Reactive oxygen species and inhibitors of inflammatory enzymes, NADPH oxidase, and iNOS in experimental models of Parkinson's disease Mediat. Inflamm. 2012 2012 823902
43. H. Kumar, B.W. Kim, S.Y. Song, J.S. Kim, I.S. Kim, Y.S. Kwon, S. Koppula, and D.K. Choi Cognitive enhancing effects of alpha asarone in amnesic mice by influencing cholinergic and antioxidant defense mechanisms Biosci. Biotechnol. Biochem. 76 2012 1518 1522
44. H. Kumar, I.S. Kim, S.V. More, B.W. Kim, Y.Y. Bahk, and D.K. Choi Gastrodin protects apoptotic dopaminergic neurons in a toxin-induced Parkinson's disease model Evid. Based Complement. Altern. Med. 2013 2013 514095
45. Y. Li, H. Nie, D. Wu, J. Zhang, X. Wei, and W. Ying Poly(ADP-ribose) polymerase mediates both cell death and ATP decreases in SIRT2 inhibitor AGK2-treated microglial BV2 cells Neurosci. Lett. 544 2013 36 40
46. X. Liang, L. Wu, Q. Wang, T. Hand, M. Bilak, L. McCullough, and K. Andreasson Function of COX-2 and prostaglandins in neurological disease J. Mol. Neurosci. 33 2007 94 99
47. G.T. Liberatore, V. Jackson-Lewis, S. Vukosavic, A.S. Mandir, M. Vila, W.G. McAuliffe, V.L. Dawson, T.M. Dawson, and S. Przedborski Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease Nat. Med. 5 1999 1403 1409
48. I.D. Limon, L. Mendieta, A. Diaz, G. Chamorro, B. Espinosa, E. Zenteno, and J. Guevara Neuroprotective effect of alpha-asarone on spatial memory and nitric oxide levels in rats injected with amyloid-beta((25-35)) Neurosci. Lett. 453 2009 98 103
49. Z. Lin, J. Gu, J. Xiu, T. Mi, J. Dong, and J.K. Tiwari Traditional chinese medicine for senile dementia Evid. Based Complement. Altern. Med. 2012 2012 692621
50. Y. Ma, S. Tian, L. Sun, S. Yao, Z. Liang, S. Li, J. Liu, L. Zang, and G. Li The effect of Acori graminei Rhizoma and extract fractions on spatial memory and Hippocampal Neurogenesis in amyloid beta 1-42 injected mice CNS Neurol. Disord. Drug Targets 14 2015 411 420
51. S. Manikandan, and R.S. Devi Antioxidant property of alpha-asarone against noise-stress-induced changes in different regions of rat brain Pharmacol. Res. 52 2005 467 474
52. F.C. Matheus, A.S. Aguiar Jr., A.A. Castro, J.G. Villarinho, J. Ferreira, C.P. Figueiredo, R. Walz, A.R. Santos, C.I. Tasca, and R.D. Prediger Neuroprotective effects of agmatine in mice infused with a single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Behav. Brain Res. 235 2012 263 272
53. K. Matsuura, H. Kabuto, H. Makino, and N. Ogawa Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion J. Neurosci. Methods 73 1997 45 48
54. M.F. McCarty Down-regulation of microglial activation may represent a practical strategy for combating neurodegenerative disorders Med. Hypotheses 67 2006 251 269
55. P.L. McGeer, and E.G. McGeer Inflammation and neurodegeneration in Parkinson's disease Park. Relat. Disord. 10 Suppl. l 2004 S3 S7
56. P.L. McGeer, C. Schwab, A. Parent, and D. Doudet Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration Ann. Neurol. 54 2003 599 604
57. M. Mogi, M. Harada, P. Riederer, H. Narabayashi, K. Fujita, and T. Nagatsu Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients Neurosci. Lett. 165 1994 208 210
58. S.V. More, H. Kumar, I.S. Kim, S. Koppulla, B.W. Kim, and D.K. Choi Strategic selection of neuroinflammatory models in Parkinson's disease: evidence from experimental studies CNS Neurol. Disord. Drug Targets 12 2013 680 697
59. S. Moriguchi, Y. Yabuki, and K. Fukunaga Reduced calcium/calmodulin-dependent protein kinase II activity in the hippocampus is associated with impaired cognitive function in MPTP-treated mice J. Neurochem. 120 2012 541 551
60. T. Muller, D. Blum-Degen, H. Przuntek, and W. Kuhn Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson's disease Acta Neurol. Scand. 98 1998 142 144
61. T. Nagatsu, M. Mogi, H. Ichinose, and A. Togari Changes in cytokines and neurotrophins in Parkinson's disease J. Neural Transm. Suppl. 2000 277 290
62. T. Nagatsu, M. Mogi, H. Ichinose, and A. Togari Cytokines in Parkinson's disease J. Neural Transm. Suppl. 2000 143 151
63. M. Nakagawa, M. Ohgoh, Y. Nishizawa, and H. Ogura Dopaminergic agonists and muscarinic antagonists improve lateralization in hemiparkinsonian rats in a novel exploratory Y-maze J. Pharmacol. Exp. Ther. 309 2004 737 744
64. K. Nakajima, and S. Kohsaka Functional roles of microglia in the central nervous system Hum. Cell. 11 1998 141 155
65. Y. Nomura NF-kappaB activation and IkappaB alpha dynamism involved in iNOS and chemokine induction in astroglial cells Life Sci. 68 2001 1695 1701
66. O.J. Onaolapo, A.Y. Onaolapo, T.J. Mosaku, O.O. Akanji, and O.R. Abiodun Elevated plus maze and y-maze behavioral effects of subchronic, oral low dose monosodium glutamate in Swiss albino mice J. Pharm. Biol. S. C. 3 2012 21 27
67. C.F. Orr, D.B. Rowe, and G.M. Halliday An inflammatory review of Parkinson's disease Prog. Neurobiol. 68 2002 325 340
68. N. Pages, P. Maurois, B. Delplanque, P. Bac, J.P. Stables, J. Tamariz, G. Chamorro, and J. Vamecq Activities of alpha-asarone in various animal seizure models and in biochemical assays might be essentially accounted for by antioxidant properties Neurosci. Res. 68 2010 337 344
69. K.L. Paumier, S.J. Sukoff Rizzo, Z. Berger, Y. Chen, C. Gonzales, E. Kaftan, L. Li, S. Lotarski, M. Monaghan, W. Shen, P. Stolyar, D. Vasilyev, M. Zaleska, D.H. Warren, and J. Dunlop Behavioral characterization of A53T mice reveals early and late stage deficits related to Parkinson's disease PLoS One 8 2013 e70274
70. R.D. Prediger, A.S. Aguiar Jr., A.E. Rojas-Mayorquin, C.P. Figueiredo, F.C. Matheus, L. Ginestet, C. Chevarin, E.D. Bel, R. Mongeau, M. Hamon, L. Lanfumey, and R. Raisman-Vozari Single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice models early preclinical phase of Parkinson's disease Neurotox. Res. 17 2010 114 129
71. S. Przedborski, V. Jackson-Lewis, R. Yokoyama, T. Shibata, V.L. Dawson, and T.M. Dawson Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity Proc. Natl. Acad. Sci. USA 93 1996 4565 4571
72. L. Qin, Y. Liu, C. Cooper, B. Liu, B. Wilson, and J.S. Hong Microglia enhance beta-amyloid peptide-induced toxicity in cortical and mesencephalic neurons by producing reactive oxygen species J. Neurochem. 83 2002 973 983
73. L. Qin, Y. Liu, T. Wang, S.J. Wei, M.L. Block, B. Wilson, B. Liu, and J.S. Hong NADPH oxidase mediates lipopolysaccharide-induced neurotoxicity and proinflammatory gene expression in activated microglia J. Biol. Chem. 279 2004 1415 1421
74. G. Raivich, M. Bohatschek, C.U. Kloss, A. Werner, L.L. Jones, and G.W. Kreutzberg Neuroglial activation repertoire in the injured brain: graded response, molecular mechanisms and cues to physiological function Brain Res. Brain Res. Rev. 30 1999 77 105
75. D. Rial, A.A. Castro, N. Machado, P. Garcao, F.Q. Goncalves, H.B. Silva, A.R. Tome, A. Kofalvi, O. Corti, R. Raisman-Vozari, R.A. Cunha, and R.D. Prediger Behavioral phenotyping of Parkin-deficient mice: looking for early preclinical features of Parkinson's disease PLoS One 9 2014 e114216
76. M. Sarter, G. Bodewitz, and D.N. Stephens Attenuation of scopolamine-induced impairment of spontaneous alteration behaviour by antagonist but not inverse agonist and agonist beta-carbolines Psychopharmacol. Berl. 94 1988 491 495
77. J.W. Shin, Y.J. Cheong, Y.M. Koo, S. Kim, C.K. Noh, Y.H. Son, C. Kang, and N.W. Sohn Alpha-asarone Ameliorates memory deficit in lipopolysaccharide-treated mice via suppression of pro-inflammatory cytokines and microglial activation Biomol. Ther. Seoul. 22 2014 17 26
78. X. Su, K.A. Maguire-Zeiss, R. Giuliano, L. Prifti, K. Venkatesh, and H.J. Federoff Synuclein activates microglia in a model of Parkinson's disease Neurobiol. Aging 29 2008 1690 1701
79. A. Suzumura, H. Takeuchi, G. Zhang, R. Kuno, and T. Mizuno Roles of glia-derived cytokines on neuronal degeneration and regeneration Ann. N. Y. Acad. Sci. 1088 2006 219 229
80. P. Teismann, and J.B. Schulz Cellular pathology of Parkinson's disease: astrocytes, microglia and inflammation Cell. Tissue Res. 318 2004 149 161
81. P. Teismann, M. Vila, D.K. Choi, K. Tieu, D.C. Wu, V. Jackson-Lewis, and S. Przedborski COX-2 and neurodegeneration in Parkinson's disease Ann. N. Y. Acad. Sci. 991 2003 272 277
82. R. Terazawa, N. Akimoto, T. Kato, T. Itoh, Y. Fujita, N. Hamada, T. Deguchi, M. Iinuma, M. Noda, Y. Nozawa, and M. Ito A kavalactone derivative inhibits lipopolysaccharide-stimulated iNOS induction and NO production through activation of Nrf2 signaling in BV2 microglial cells Pharmacol. Res. 71 2013 34 43
83. J.L. Tillerson, W.M. Caudle, M.E. Reveron, and G.W. Miller Detection of behavioral impairments correlated to neurochemical deficits in mice treated with moderate doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Exp. Neurol. 178 2002 80 90
84. Y. Watanabe, H. Kato, and T. Araki Protective action of neuronal nitric oxide synthase inhibitor in the MPTP mouse model of Parkinson's disease Metab. Brain Dis. 23 2008 51 69
85. P.S. Whitton Inflammation as a causative factor in the aetiology of Parkinson's disease Br. J. Pharmacol. 150 2007 963 976
86. H. Wilms, P. Rosenstiel, J. Sievers, G. Deuschl, L. Zecca, and R. Lucius Activation of microglia by human neuromelanin is NF-kappaB dependent and involves p38 mitogen-activated protein kinase: implications for Parkinson's disease FASEB J. 17 2003 500 502
87. X.F. Wu, M.L. Block, W. Zhang, L. Qin, B. Wilson, W.Q. Zhang, B. Veronesi, and J.S. Hong The role of microglia in paraquat-induced dopaminergic neurotoxicity Antioxid. Redox Signal 7 2005 654 661
88. J. Zhang, N. Niu, M. Wang, M.A. McNutt, D. Zhang, B. Zhang, S. Lu, Y. Liu, and Z. Liu Neuron-derived IgG protects dopaminergic neurons from insult by 6-OHDA and activates microglia through the FcgammaR I and TLR4 pathways Int. J. Biochem. Cell. Biol. 45 2013 1911 1920